Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig<sup>®</sup>]) in the treatment of patients with primary immunodeficiencies.

Kobayashi, Roger H; Gupta, Sudhir; Melamed, Isaac; Mandujano, J Fernando; Kobayashi, Ai Lan; Ritchie, Bruce; Geng, Bob; Atkinson, Thomas Prescott; Rehman, Syed; Turpel-Kantor, Eva; Litzman, Jirí

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig^®]) in the treatment of patients with primary immunodeficiencies.

Kobayashi, Roger H; Gupta, Sudhir; Melamed, Isaac; Mandujano, J Fernando; Kobayashi, Ai Lan; Ritchie, Bruce; Geng, Bob; Atkinson, Thomas Prescott; Rehman, Syed; Turpel-Kantor, Eva; Litzman, Jirí.

Afiliação

Kobayashi RH; UCLA School of Medicine, Los Angeles, CA, United States.
Gupta S; Division of Basic and Clinical Immunology, University of California, Irvine, Irvine, CA, United States.
Melamed I; IMMUNOe Research Center, Centennial, CO, United States.
Mandujano JF; Pediatric Pulmonary Associates of North Texas, Frisco, TX, United States.
Kobayashi AL; Midlands Pediatrics, Papillion, NE, United States.
Ritchie B; Divisionof Hematology, Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada.
Geng B; Divisions of Adult and Pediatric Allergy and Immunology, University of California, San Diego, La Jolla, CA, United States.
Atkinson TP; Department of Pediatric Allergy, Asthma and Immunology, University of Alabama, Birmingham, AL, United States.
Rehman S; Allergy and Asthma Center Inc., Toledo, OH, United States.
Turpel-Kantor E; Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria.
Litzman J; Department of Clinical Immunology and Allergology, St Anne's University Hospital in Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.